149 related articles for article (PubMed ID: 34671564)
1. Case Report: A Pancreatic Ductal Adenocarcinoma Patient With Concurrent Targetable Somatic Novel KANK1-ALK, UPP2-NTRK3 Fusion, and Pathogenetic Germline BRCA Mutation.
Meng F; Lu L; Tan Y; Duan Q; Lu H
Front Oncol; 2021; 11():757965. PubMed ID: 34671564
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterisation of pancreatic ductal adenocarcinoma with
Allen MJ; Zhang A; Bavi P; Kim JC; Jang GH; Kelly D; Perera S; Denroche RE; Notta F; Wilson JM; Dodd A; Ramotar S; Hutchinson S; Fischer SE; Grant RC; Gallinger S; Knox JJ; O'Kane GM
J Clin Pathol; 2023 Mar; 76(3):158-165. PubMed ID: 34583947
[TBL] [Abstract][Full Text] [Related]
3. Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
Sorscher S; Ramkissoon S
Oncologist; 2021 Nov; 26(11):916-918. PubMed ID: 34309133
[TBL] [Abstract][Full Text] [Related]
4. Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment.
Peters ML; Tseng JF; Miksad RA
Clin Ther; 2016 Jul; 38(7):1622-35. PubMed ID: 27041411
[TBL] [Abstract][Full Text] [Related]
5. Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma.
Huffman BM; Ellis H; Jordan AC; Freed-Pastor WA; Perez K; Rubinson DA; Sethi N; Singh H; Surana R; Wolpin BM; Aguirre AJ; Cleary JM
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551707
[TBL] [Abstract][Full Text] [Related]
6. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
[TBL] [Abstract][Full Text] [Related]
7. An Oncogenic
Shimada Y; Kohno T; Ueno H; Ino Y; Hayashi H; Nakaoku T; Sakamoto Y; Kondo S; Morizane C; Shimada K; Okusaka T; Hiraoka N
Oncologist; 2017 Feb; 22(2):158-164. PubMed ID: 28167572
[TBL] [Abstract][Full Text] [Related]
8. Identification of Targetable
Singhi AD; Ali SM; Lacy J; Hendifar A; Nguyen K; Koo J; Chung JH; Greenbowe J; Ross JS; Nikiforova MN; Zeh HJ; Sarkaria IS; Dasyam A; Bahary N
J Natl Compr Canc Netw; 2017 May; 15(5):555-562. PubMed ID: 28476735
[TBL] [Abstract][Full Text] [Related]
9. Management of BRCA Mutation Carriers With Pancreatic Adenocarcinoma.
Golan T; Hammel P
J Natl Compr Canc Netw; 2021 Apr; 19(4):469-473. PubMed ID: 33845459
[TBL] [Abstract][Full Text] [Related]
10. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma.
Botrus G; Kosirorek H; Sonbol MB; Kusne Y; Uson Junior PLS; Borad MJ; Ahn DH; Kasi PM; Drusbosky LM; Dada H; Surapaneni PK; Starr J; Ritter A; McMillan J; Wylie N; Mody K; Bekaii-Saab TS
Oncologist; 2021 Jul; 26(7):569-578. PubMed ID: 33555095
[TBL] [Abstract][Full Text] [Related]
11. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
[TBL] [Abstract][Full Text] [Related]
12. Targeting DNA damage repair pathways in pancreas cancer.
Crowley F; Park W; O'Reilly EM
Cancer Metastasis Rev; 2021 Sep; 40(3):891-908. PubMed ID: 34403012
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic ductal adenocarcinoma in the era of precision medicine.
Zheng-Lin B; O'Reilly EM
Semin Oncol; 2021 Feb; 48(1):19-33. PubMed ID: 33637355
[TBL] [Abstract][Full Text] [Related]
14. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
15. BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients.
Park JH; Jo JH; Jang SI; Chung MJ; Park JY; Bang S; Park SW; Song SY; Lee HS; Cho JH
Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008403
[TBL] [Abstract][Full Text] [Related]
16. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
17. OncoPan
Tibiletti MG; Carnevali I; Pensotti V; Chiaravalli AM; Facchi S; Volorio S; Mariette F; Mariani P; Fortuzzi S; Pierotti MA; Sessa F
Biomedicines; 2022 May; 10(5):. PubMed ID: 35625944
[TBL] [Abstract][Full Text] [Related]
18. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
Moffat GT; O'Reilly EM
Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
[TBL] [Abstract][Full Text] [Related]
19. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma.
Blair AB; Groot VP; Gemenetzis G; Wei J; Cameron JL; Weiss MJ; Goggins M; Wolfgang CL; Yu J; He J
J Am Coll Surg; 2018 Apr; 226(4):630-637.e1. PubMed ID: 29309945
[TBL] [Abstract][Full Text] [Related]
20. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.
Philip PA; Azar I; Xiu J; Hall MJ; Hendifar AE; Lou E; Hwang JJ; Gong J; Feldman R; Ellis M; Stafford P; Spetzler D; Khushman MM; Sohal D; Lockhart AC; Weinberg BA; El-Deiry WS; Marshall J; Shields AF; Korn WM
Clin Cancer Res; 2022 Jun; 28(12):2704-2714. PubMed ID: 35302596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]